Post Operative Pain Management for ACL Reconstruction
Primary Purpose
Pain, Postoperative
Status
Enrolling by invitation
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Bupivacaine HCl 0.5% Injectable Solution
Dexamethasone
Infiltration between Popliteal Artery and Capsule of the knee (iPACK)
Percocet 5Mg-325Mg Tablet
Sponsored by
About this trial
This is an interventional prevention trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- All patients undergoing primary ACLR for ACL tear, including patients with concomitant meniscectomy or meniscal repair.
Exclusion Criteria:
- Revision ACLR, worker's compensation, pregnancy, age<18 years
Sites / Locations
- Rothman Orthopaedic Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
isolated adductor canal block (ACB)
isolated adductor canal block (ACB) + IPACK
Arm Description
Adductor Canal Block with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone.
ACB with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone, and iPACK with 20cc 0.5% bupivacaine + 2mg dexamethasone.
Outcomes
Primary Outcome Measures
Post operative pain management
This will be measured by the participants completing a pain and medication Use questionnaire
Post operative pain management 2
Participants will also complete the International Knee Documentation Committee (IKDC) questionnaires
Secondary Outcome Measures
Full Information
NCT ID
NCT05316168
First Posted
December 2, 2021
Last Updated
September 18, 2023
Sponsor
Rothman Institute Orthopaedics
1. Study Identification
Unique Protocol Identification Number
NCT05316168
Brief Title
Post Operative Pain Management for ACL Reconstruction
Official Title
Isolated Adductor Canal Block vs Adductor Canal Block With IPACK in ACL Reconstruction: A Randomized, Prospective Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
September 30, 2023 (Anticipated)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rothman Institute Orthopaedics
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
Health care providers are seeking methods to limit post-operative pain and opioid prescriptions to reduce the burden of the national opioid use epidemic. Adductor canal block (ACB) is a peripheral nerve block that has been shown to reduce pain and opioid usage with minimal effect on quadriceps function in patients undergoing arthroscopic knee surgery. Infiltration between Popliteal Artery and Capsule of the Knee (iPACK) block has also shown promise in reducing pain and opioid usage, specifically reducing posterior knee pain, which ACB is not able to achieve. To our knowledge, there is currently no study in the orthopedic literature comparing post-operative pain and opioid consumption in ACL reconstruction (ACLR) patients who received isolated ACB versus ACB with IPACK.
The primary aim of this study is to investigate the role of IPACK in combination with ACB in reducing peri-operative (14-days) pain levels in ACLR patients. The secondary aim is to determine the effectiveness of IPACK in reducing post-operative opioid use. The tertiary aim is to determine any effect of IPACK on post-operative functional outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
154 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
isolated adductor canal block (ACB)
Arm Type
Active Comparator
Arm Description
Adductor Canal Block with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone.
Arm Title
isolated adductor canal block (ACB) + IPACK
Arm Type
Active Comparator
Arm Description
ACB with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone, and iPACK with 20cc 0.5% bupivacaine + 2mg dexamethasone.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine HCl 0.5% Injectable Solution
Intervention Description
During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
During adductor canal block participants will receive 2mg Dexamethasone
Intervention Type
Procedure
Intervention Name(s)
Infiltration between Popliteal Artery and Capsule of the knee (iPACK)
Intervention Description
Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
Intervention Type
Drug
Intervention Name(s)
Percocet 5Mg-325Mg Tablet
Intervention Description
Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
Primary Outcome Measure Information:
Title
Post operative pain management
Description
This will be measured by the participants completing a pain and medication Use questionnaire
Time Frame
14 days
Title
Post operative pain management 2
Description
Participants will also complete the International Knee Documentation Committee (IKDC) questionnaires
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
All patients undergoing primary ACLR for ACL tear, including patients with concomitant meniscectomy or meniscal repair.
Exclusion Criteria:
Revision ACLR, worker's compensation, pregnancy, age<18 years
Facility Information:
Facility Name
Rothman Orthopaedic Institute
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Post Operative Pain Management for ACL Reconstruction
We'll reach out to this number within 24 hrs